Physician profile
Anna E Karp
NPI 1487942223
$13,642.86
in general payments reported to CMS, 2019-2025
29 companies · $4,599 in 2025
The $4,599 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $850 · 2021: $1,438 · 2022: $1,493 · 2023: $2,956 · 2024: $2,047 · 2025: $4,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,222 · Consulting Fee: $1,050 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,221.66 |
| Consulting Fee | $1,050.00 |
| Education | $329.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,856.89 | 2019-2025 | |
| Janssen Biotech, INC. | $2,613.81 | 2020-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,258.82 | 2019-2025 | Winlevi, Ilumya |
| Lilly USA, LLC | $986.92 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $808.99 | 2019-2025 | Nemluvio, Twyneo, Aklief |
| Pfizer INC. | $622.98 | 2020-2025 | |
| Dermavant Sciences, INC. | $541.05 | 2022-2023 | Vtama |
| Amgen INC. | $516.41 | 2020-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $470.22 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $406.19 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $365.44 | 2023-2025 | Sotyktu |
| Incyte Corporation | $330.61 | 2021-2025 | Opzelura |
| Genzyme Corporation | $317.54 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $290.62 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $263.79 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $201.65 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $172.06 | 2019-2025 | Jublia, Cabtreo, Duobrii |
| Revance Therapeutics, INC. | $150.00 | 2025 | Daxxify |
| Organon LLC | $134.08 | 2025 | Vtama |
| Ucb, INC. | $111.75 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $58.25 | 2020-2024 | |
| Botanix Sb INC | $33.28 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.00 | 2023 | Cyltezo |
| Promius Pharma LLC | $20.70 | 2019 | |
| Kyowa Kirin, INC. | $18.75 | 2020 | |
| Lnhc, INC | $17.62 | 2025 | Zelsuvmi |
| Almirall LLC | $17.47 | 2019 | |
| Dermira, INC. | $14.00 | 2020 | |
| Strata Skin Sciences, INC. | $13.97 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Karp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.